 
   
 
Clinical Evaluation of a Monthly Replacement Daily Wear 
Silicone Hydrogel Multifocal Toric Contact [CONTACT_674791]624‐M103 
 
 
PROTOCOL and STATISTICAL ANALYSIS PLAN 
 
 
[STUDY_ID_REMOVED] 
Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 1 of 17 
 
Alcon – Business Use Only   
Feasibility Clinical Protocol  for CLR624 -M103  
Title: Assessing the Clinical Performance of Two Frequent Replacement 
Silicone Hydrogel Multifocal Toric Contact [CONTACT_674792]:  CLR624 -M10 3, Version 1.0  
Sponsor Name [CONTACT_13311]:  Alcon Research, LLC and its affiliates (“Alcon ”) 
[ADDRESS_912067](s):  MFT SiHy Contact [CONTACT_32993]; LID223188  
 
Property of Alcon  
Confidential  
May not be u sed, divulged, published, or otherwise disclosed without the consent of 
Alcon  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 2 of 17 
 
Alcon – Business Use Only  Investigator Agreement:  
• I have read the Feasibility Clinical Protocol described herein and the 
Feasibility Clinical Protocol governing it, recognize its confidentiality, and 
agree to conduct the described trial in compliance with Good Clinical Practice 
(GCP), the ethical principles contained within the Declaration of Helsinki, this 
protocol, all applicable regulatory authority regulations, and conditions o f approval 
imposed by [CONTACT_199135].  
• I will supervise all testing of the device involving human subjects and ensure that 
the requirements relating to obtaining informed consent and IRB review and 
approval are met in accordance w ith applicable local and governmental regulations.  
• I have read and understand the appropriate use of the investigational product(s) as 
described in the protocol, current Investigator ’s Brochure, product information, or 
other sources provided by [CONTACT_456] . 
• I understand the potential risks and side effects of the investigational product(s).  
• I agree to maintain adequate and accurate records in accordance with government 
regulations and to make those records available for inspection.  
• I agree to comply with al l other requirements regarding the obligations of clinical 
investigator s and all other pertinent requirements of the sponsor  and government 
agencies.  
• I agree to ensure that all associates, colleagues, and employees assisting in the 
conduct of the study are  informed of their obligations in meeting the above 
commitments.  
Have you ever been disqualified as an investigator  by [CONTACT_34699]?  
 No        Yes 
Have you ever been involved in a study or other research that was terminated?  
 No        Yes 
If yes, please explain here:  
 
 
Principal investigator : 
 [INVESTIGATOR_199128]:   
Address:   
 
  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 3 of 17 
 
Alcon – Business Use Only  Table of Contents  
Feasibility Clinical Protocol for CLR624 -M103 ................................ ................................  [ADDRESS_912068] and Associated Materials  ................................ ...........................  11 
1.4 Study -Specific Lens Returns  ................................ ................................ .............  17 
1.4.1  Worn IP  ................................ ................................ .............................. 17 
1.4.2  Lens Ret urn (ADE/Device Deficiency)  ................................ ............. [ADDRESS_912069] of Tables  
Table  1-1 Schedule of Study Procedures and Assessments  ................................ .............  13 
 

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 4 of 17 
 
Alcon – Business Use Only  Abbreviations and Acronyms  
Abbreviation  Definition  
ADE  Adverse device effect  
AE Adverse event  
BCV A  Best corrected visual acuity  
°C Degrees Celsius  
CDMA  Clinical Development & Medical Affairs  
CSS Clinical Site Specialist  
CT&OL  Clinical Trial & Operations Lead  
D Diopter(s)  
eCRF  Electronic case report form  
ESP Eye Surface Profiler  
GA Georgia  
GCP  Good Clinical Practice  
ICF Informed consent form  
ID Identification  
IP Investigational product  
IRB Institutional review board  
JCR Johns Creek Research  
LID Lens identification number  
logMAR  Logarithm of the minimum angle of resolution  
  
MFT  Multifocal toric contact [CONTACT_674793] [INVESTIGATOR_199129]  
R&D  Research & Development  
SADE  Serious adverse device effect  
SiHy  Silicone hydrogel  
US or [LOCATION_003]  [LOCATION_002]  
VA Visual acuity  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 5 of 17 
 
Alcon – Business Use Only   
[ADDRESS_912070] lens to aid in 
confirmation of the study lens design.  
Investigator(s)  
Site Johns Creek Research Clinic  
[ADDRESS_912071]  
Johns Creek, GA, [ZIP_CODE] [LOCATION_003]  
External 
Organizations  Not Applicable  
Planned Duration 
of Exposure  ~4 days total (test and comparator)  
Test Product: LID223188  for 2 (+3) days   
Comparator  Product: Ultra MFT  for 2 (+3) days   
Number of Subjects  Planned to enroll: ~30 Target to comp lete: [ADDRESS_912072] lens 
wearing experience .  
 
  
 
 
 
 
Lens Assignment  Subjects will not be randomized in this study  
Study Design   Prospective   Single -masked (trial subject)  
 Open -label   Randomized  
 Pre-determined order  
• Even subject #: Lens Pair 1 
– LID2 [ZIP_CODE], Lens Pair 2 – 
Ultra MFT  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 6 of 17 
 
Alcon – Business Use Only  Protocol Study Details  
• Odd subject #: Len s Pair 1 – 
Ultra  MFT , Lens Pair 2 – 
LID2 [ZIP_CODE]  
 Single group  
 Parallel group  
 Crossover  
 Other   Contralateral  
 Bilateral  
 Monocular lens wear  
Visit Schedule:  
1. Visit 1: Screening/ Baseline/Dispense Lens Pair 1 
2. Visit 2 (2 (+3) days after Visit 1): Follow -up Lens Pair 1 (to 
occur at least 4 -6 hours after lens insertion) /Dispense Lens Pair 
2 
3. Visit 3 (2 (+3) days after Visit 2): Follow -up Lens Pair 2 (to 
occur at least 4 -6 hours after lens insertion)/Exit  
 
 
 
Decision Criteria  No prospective decision criteria have been defined for this study.  
Assessments  1. V A with study lenses ( logMAR; distance @ 4m: OU,  
 

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 7 of 17 
 
Alcon – Business Use Only  Protocol Study Details  
Safety Assessments  1. AEs 
2. Biomicroscopy  
3. Device deficiencies  
Inclusion Criteria  1. Subject must be at least [ADDRESS_912073] sign an informed 
consent form (ICF) that has been approved by [CONTACT_84786] (IRB).  
3. Currently wears multifocal soft contact [CONTACT_674794] [ADDRESS_912074] cylinder power between -0.75 D and -1.00 D   
5. BCV A logMAR 0.1  (Snellen 20/25 ) or better in each eye.  
6. Subject must be willing to stop wearing habitual lens for the 
study duration and able to fit with available contact [CONTACT_674795] 
(see Section 1.3).  
7. Subject must possess spectacles that provide a corrected visual 
acuity of 20/40 or better OU .  
Exclusion Criteria  1. Any anteri or segment infection, inflammation, or abnormality or 
disease (including systemic) that contraindicates contact [CONTACT_94638], as determined by [CONTACT_093] . 
2. Any use of systemic or ocular medications for which contact 
[CONTACT_66218], as  determined by [CONTACT_1275] . 
3. History of refractive surgery or plan to have refractive surgery 
during the study or irregular cornea in either eye.  
4. Ocular or intraocular surgery (excluding placement of punctal 
plugs) within the previous 12 months or plan ned during the 
study.  
5. Biomicroscopy findings at screening that are moderate (Grade 3) 
or higher and/or corneal vascularization that is mild (Grade 2) or 
higher, and/or any infiltrate.  

Document ID:  
V-CLN -0025584Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 8 of 17 
Alcon – Business Use Only  Protocol Study Details  
6.Current or history of pathologically dry eye in either eye that, in
the opi[INVESTIGATOR_871] , would preclude contact [CONTACT_674796].
7.Current or history of herpetic keratitis in either eye.
8.Eye injury in either eye within 12 weeks immediately prior to
enrollment for this trial.
9.Current or history of intolerance, hypersensitivity , or allergy to
any component of the study products.
10.The investigator , his/her staff, family members of the
investigator , family members of the investigator ’s staff, or
individuals living in the households of the aforementioned
persons may not participate in the study.
11.Participation of the subject in a clinical trial within the previous
[ADDRESS_912075] or lens naming conventions will be used: 
•
•Ultra MFT
Subject 
Characteristics 
and Study 
Conduct 
Summaries  The following will be presented : 
•Conduct
•Demographics
•Ct.gov AE table
Assessment 
Analysis Strategy  Several effectiveness assessments are being conducted in this study. 
Results from selected assessment will be summarized using 
descriptive statistics according to its measurement scale. Listings 
will be provided as necessary.  
The Safety Analysis Set will serve as the analysis data set for all 
effectiveness analyses.  
Planned 
Effectiveness  
Analyses  The following assessments will be summarized with descriptive 
statistics, and listings will be generated when applicable:   

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 9 of 17 
 
Alcon – Business Use Only  Protocol Study Details  
Title Assessment  Analysis  
V A with study 
lenses  Visual Acuity  
• 4m (OU, 
 Listing, table for 
continuous variables 
(Dispense, Follow -
up) 

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 10 of 17 
 
Alcon – Business Use Only  Protocol Study Details  
 
 
Interim Analysis  At the discretion of the CDMA Project Lead, interim evaluations 
may be undertaken to provide early insight into product safety 
and/or effectiveness.  
Sample Size and 
Power 
Calculations  No formal sample size calculation is provided given the descriptive 
and feasibility nature of the study.  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 11 of 17 
 
Alcon – Business Use Only  1.[ADDRESS_912076] 1  
/LID223188  Comparator  Product 1  
Ultra MFT  
Primary 
component/ 
material  Lehfilcon A  Samfilcon A  
Manufacturer  Alcon Laboratories, Inc.  Bausch + Lomb  
Power Range  Any combination of the following, as available:  
• Sphere: Plano to -4.00D in 1D steps  
• Cyl: -0.75D  
• Axis: 170, 180, 010, 090  
• Add: Lo, Med, Hi  Any combination of the following, as available:  
• Sphere: Plano to -4.25D in 0.25D steps  
• Cyl: -0.75D  
• Axis: 170, 180, 010, 090  
• Add: Lo, Hi 
Supply  The sponsor will provide this test product.  The site will procure this comparator product.  
Packaging and 
Labeling  Primary label on blister foil pack includes:  
• material name [CONTACT_231493]  
• base curve  
• diameter  
• packing solution  
• power  
• lot number  
• expi[INVESTIGATOR_320]  
• content statement  
• investigational device statement  
• sponsor information  
• country of origin  
Secondary color -coded label on packages  Commercial primary label on blister foil pack.  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 12 of 17 
 
Alcon – Business Use Only   Test Product 1  
/LID223188  Comparator  Product 1  
Ultra MFT  
includes:  
• clinical protocol number  
• material name [CONTACT_231493]  
• power  
• an investigational use only statement  
• tracking or handling unit number  
Storage  Lenses should be stored at room temperature.  Refer to manufacturer ’s instructions.  
Other  Replacement lenses are allowed  only if there is a device deficiency (e.g., torn lens) or if the lens falls on the 
ground and investigator wants to insert a new lens.  
Associated 
Materials  • CLEAR CARE Cleaning and Disinfecting Solution will be used with study lenses for the duration of 
study.  
• LacriPure rinsing/reinsertion PRN will be used as needed with study lenses.  
• Lubrication/re -wetting drops will not be permitted during study lens wear.  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 15 of 17 
 
Alcon – Business Use Only   
Procedure / Assessment  Visit 1  Visit 2  Visit 3  
Unscheduled 
Visit / Early 
Exit Visit  Source 
Only * Screening / Baseline / 
Dispense Pair 1  Follow -up Pair 1  
(2 [+3] days after 
Visit 1)  Dispense Pair 2  Follow up Pair 2  
(2 [+3] days after 
Visit 3) / Exit  

Document ID:  
V-CLN -0025584  Status: Approved , Version: 1.0 
Approved Date: 24 May 2023  Page 17 of 17 
 
Alcon – Business Use Only  1.4 Study -Specific Lens Returns  
1.4.1 Worn IP  
Worn IP will be returned to the sponsor. Use the following instructions for collection, storage, 
and shippi[INVESTIGATOR_007], unless otherwise instructed by [CONTACT_456].  
• Removal from eye: Clean hands  
• Storage container: Unused screw -top lens case  
• Label information:  
o Protocol n umber  
o Site number  
o Subject ID  
o Eye 
o Lens type/ identification  
o Date collected  
• Storage solution: PURILENS Plus Preservative Free Saline (PURILENS Plus Saline)  
• Storage temperature: Refrigerated 4 -10°C  
• Timing of return: Study Completion  
• An inventory/list of lense s being returned  
1.4.2 Lens Return (ADE/Device Defic iency)  
The directions for the collection, storage , and return of lenses associated with an AE or 
device deficiency are listed in the  Protocol.  
 
